Pier P Scaglioni MD
Hematologic Oncology
Professor Department of Internal Medicine Division of Hematology/Oncology Medical Director UC Health Barrett Cancer Center University of Cincinnati Medical College 3125 Eden Avenue, Rm. 3118 Cincinnati, OH 45219-2293
Join to view full profile
3130 Highland AveCincinnati, OH 45219
Phone+1 513-475-8500
Fax+1 513-584-4281
Dr. Scaglioni is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Pier Scaglioni is an oncologist in Cincinnati, OH and is affiliated with University of Cincinnati Medical Center. He received his medical degree from University of Modena Faculty of Medicine and has been in practice 28 years. He also speaks multiple languages, including Italian and Spanish. He specializes in hematologic oncology and is experienced in acute leukemias and malignant hematology.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2001 - 2004
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 1998 - 2001
University of Modena Faculty of MedicineClass of 1989
Certifications & Licensure
OH State Medical License 2017 - 2028
TX State Medical License 2007 - 2018
NY State Medical License 2001 - 2007
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
Publications & Presentations
PubMed
- Thioredoxin Reductase 1 inhibition triggers ferroptosis in KRAS-independent lung cancers.Cristina Andreani, Caterina Bartolacci, Margherita Melegari, Nicola Sargentoni, Lorenzo Luciani
Biorxiv. 2025-07-30 - 4 citationsCopper Drives Remodeling of Metabolic State and Progression of Clear Cell Renal Cell Carcinoma.Megan E Bischoff, Behrouz Shamsaei, Juechen Yang, Dina Secic, Bhargav Vemuri
Cancer Discovery. 2025-02-07 - 4 citationsCoordinated Targeting of S6K1/2 and AXL Disrupts Pyrimidine Biosynthesis in PTEN-Deficient Glioblastoma.Catherine A Behrmann, Kelli N Ennis, Pranjal Sarma, Collin Wetzel, Nicholas A Clark
Cancer Research Communications. 2024-08-01
Press Mentions
CDK4/6 Inhibitors Explored in KRAS-Mutant CancersOctober 31st, 2017
Grant Support
- Fatty acid metabolism regulates ferroptosis in mutant KRAS lung cancerUNIVERSITY OF CINCINNATI2022–2026
- Defining and Defeating Mechanistic Subtypes of KRAS-mutant Lung CancersCPRIT2016–Present
- Mutant KRAS reprograms lipid metabolism exposing beta-oxidation as a novel therapeutic target in lung cancer lung cancerCPRIT2014–Present
- Post-Graduate Hematology/Oncology Translational (PG-HOT) Training ProgramUNIVERSITY OF CINCINNATI2019–2025
- Identification of critical components of the K-RAS network in lung cancerAmerican Cancer Society Scholar Award2012–2017
Other Languages
- Italian, Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
